Company facts
- Headquarters
- Dallas, Texas
- Most recent report
- 10-Q, filed Aug 6, 2026
- Incorporated
- Delaware
- Filings on record
- 230 filings
- On EDGAR
- CIK 1991792
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 11
News 8 of 29
Prospectuses and Registrations 8 of 12
- 424B5 Prospectus supplement for an offering Aug 6, 2026
- S-8 Registration statement for an employee plan Feb 27, 2026
- 424B5 Prospectus supplement for an offering Jan 13, 2026
- S-3ASR Automatic shelf registration Mar 28, 2025
- 424B4 Final prospectus for an offering Dec 13, 2024
- S-1/A Registration statement for an offering, amended Dec 11, 2024
- S-1 Registration statement for an offering Dec 11, 2024
- S-8 Registration statement for an employee plan Jan 26, 2024
Proxies 4
Ownership 8 of 152
- 144 Notice of a proposed sale of restricted stock Aug 19, 2026
- 4 Insider reported a trade Aug 18, 2026
- 144 Notice of a proposed sale of restricted stock Aug 17, 2026
- 144 Notice of a proposed sale of restricted stock Aug 14, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- 144 Notice of a proposed sale of restricted stock Aug 13, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 13, 2026
Other 8 of 22
- ARS Annual report sent to shareholders Apr 24, 2026
- ARS Annual report sent to shareholders Apr 25, 2025
- EFFECT Notice that a registration became effective Dec 12, 2024
- CORRESP Reply to SEC staff Dec 11, 2024
- CORRESP Reply to SEC staff Dec 11, 2024
- UPLOAD Comment letter from SEC staff Nov 21, 2024
- DRS Draft registration statement, submitted confidentially Nov 14, 2024
- SEC STAFF LETTER Jan 26, 2024
Everything here comes from CG Oncology, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.